ACST Acasti Pharma: ערך חשבונאי למניה

Stable demand for cardiology drugs is being constrained by sanction pressure on logistics, which is confirmed by the current book value of the share, where GURU.Markets data forms this chart and the indicator stands at 5.84. Acasti Pharma (ACST) is creating effective drug delivery methods for rare pathologies, scaling clinical trials in neurology and developing its own IT platform for pharmaceutical partnerships.

Long-term risk control requires monitoring equity per share, which allows for an assessment of the real value of net assets excluding debt. The current value of 5.84 and the trajectory of the book value per share confirm the effectiveness of the asset-light strategy of Acasti Pharma (ACST): the absence of production costs shifts capital into intellectual property, transforming patents into the foundation for future high-margin royalties.